SOD1 and amyotrophic lateral sclerosis: To exclude that this incongruence between 3 and 12 months on tofersen might have occurred due to selection bias in the discovery cohort (composed of the 9 patients with the most profound reduction of neurofilament levels in the first German cohort of tofersen‐treated SOD1‐ALS patients5), we specifically looked at the effect of 12 months of tofersen on these individuals.